Fludarabine/Cyclophosphamide/Rituxan is an effective regimen for non-myeloablative allogeneic stem cell transplantation (SCT) for lymphoid malignancies.

被引：0
|
作者：
Berkahn, LC [1 ]
Simpson, DR [1 ]
Raptis, A [1 ]
Klingemann, HG [1 ]
机构：
[1] Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5274
引用
收藏
页码：352B / 352B
页数：1
相关论文
共 50 条
  • [21] T-cell replete fludarabine/cyclophosphamide reduced intensity allogeneic stem cell transplantation for lymphoid malignancies
    Auer, Rebecca L.
    MacDougall, Finlay
    Oakervee, Heather E.
    Taussig, David
    Davies, Jeff K.
    Syndercombe-Court, Denise
    Agrawal, Samir
    Cavenagh, Jamie D.
    Lister, T. Andrew
    Gribben, John G.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 (05) : 580 - 585
  • [22] A non-myeloablative regimen of fludarabine and melphalan is safe and well tolerated for allogeneic transplantation in multiple myeloma
    Qazilbash, Muzaffar H.
    Saliba, Rima M.
    Parikh, Gaurav C.
    Hosing, Chitra
    Mendoza, Floralyn
    Weber, Donna M.
    Wang, Michael
    Thomas, Sheeba K.
    Flosser, Thuy S.
    Kebriaei, Partow
    Popat, Uday
    Alousi, Amin M.
    De Lima, Marcos
    Champlin, Richard E.
    Giralt, Sergio A.
    BLOOD, 2007, 110 (11) : 890A - 890A
  • [23] Update on non-myeloablative stem cell transplantation for hematologic malignancies
    Giralt, S
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2002, 76 : 368 - 375
  • [24] Allogeneic PBSC transplantation after non-myeloablative regimen containing busulfan, fludarabine, and ATG.
    Mayer, J
    Krahulová, M
    Korístek, Z
    Vorlícek, J
    BONE MARROW TRANSPLANTATION, 1999, 23 : S23 - S23
  • [25] Safe and effective use of outpatient non-myeloablative allogeneic stem cell transplantation for myeloma
    Campbell, P.
    Walker, P.
    Avery, S.
    Patil, S.
    Curtis, D.
    Schwarer, A.
    Wei, A.
    Kalff, A.
    Muirhead, J.
    Spencer, A.
    BLOOD CANCER JOURNAL, 2014, 4 : e213 - e213
  • [26] Non-myeloablative allogeneic stem cell transplantation in mantle cell lymphoma
    Le Gouill, S.
    Kroeger, N.
    Dhedin, N.
    Nagler, A.
    Bouabdallah, K.
    Yakoub-Agha, I.
    Bulabois, C-E
    Buzyn, A.
    Rio, B.
    Moles, M-P.
    Shimoni, A.
    Guillaume, T.
    Milpied, N.
    Leux, C.
    Harousseau, J-L.
    Mohty, M.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S67 - S67
  • [27] ALLOGENEIC TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING WITH FLUDARABINE/CYCLOPHOSPHAMIDE IS FEASIBLE AND EFFECTIVE FOR HIGHLY RESISTANT INDOLENT AND AGGRESSIVE LYMPHOID MALIGNANCIES.
    Wondergem, M.
    Dijkstra, F.
    Visser, O.
    Zweegman, S.
    Ossenkoppele, G.
    Witte, B.
    Janssen, J.
    HAEMATOLOGICA, 2013, 98 : 655 - 655
  • [28] Comparison Between Busulfan with Cyclophosphamide and Busulfan with Fludarabine As Myeloablative Conditioning of Allogeneic Hematopoietic Stem Cell Transplantation for Myeloid Malignancies
    Mori, Takehiko
    Ohashi, Kazuteru
    Kanamori, Heiwa
    Sakura, Toru
    Yano, Shingo
    Kanda, Yoshinobu
    Kako, Shinichi
    Tachibana, Takayoshi
    Yokota, Akira
    Onizuka, Makoto
    Nakaseko, Chiaki
    Okamoto, Shinichiro
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S204 - S204
  • [29] Non-myeloablative therapy (NMA) and allogeneic stem cell transplantation (SCT) complicated by progressive multifocal leukoencephalopathy (PML).
    Buckanovich, RJ
    Luger, SM
    Stricker, C
    Laport, GG
    Schuster, S
    Stadtmauer, EA
    Pruitt, A
    Liu, G
    Porter, DL
    BLOOD, 2000, 96 (11) : 345B - 345B
  • [30] Non-myeloablative conditioning regimen in Allogeneic Peripheral Blood Stem Cell Transplantation (AlloPBSCT) for high-risk Hematologic Malignancies (HM)
    Vaz, CP
    Campilho, F
    Campos, A
    Carvalhais, A
    Roncon, S
    Martinho, A
    Duarte, R
    Raimundo, A
    Avila, A
    Pimentel, P
    BONE MARROW TRANSPLANTATION, 2001, 27 : S293 - S293
12345